Abstract
Since the introduction of anti-TNF agents for the treatment of Crohn's disease there has been interest in the potential for treating ulcerative colitis with biological therapies. Early observational series suggested a benefit in the setting of severe, hospitalized patients. However, the recent completion of two large multi-center, double-blind placebo-controlled trials confirmed a role for infliximab for outpatients with refractory, moderate-severe disease with evidence for clinical remissions, mucosal healing, and a reduction in colectomies. Despite this evidence, there are numerous questions remaining regarding the optimal positioning in the setting of moderate-severe disease, potential benefits of concomitant immune suppression and the need for maintenance treatment after induction therapy. Additional clinical trials have demonstrated a less profound benefit for adalimumab at similar doses that are used in Crohn's disease. Other biological agents that have targeted T cells such as visiluzimab and abatacept were not demonstrated to be effective in controlled trials.
Original language | English (US) |
---|---|
Pages (from-to) | 497-500 |
Number of pages | 4 |
Journal | Digestive Diseases |
Volume | 28 |
Issue number | 3 |
DOIs | |
State | Published - Oct 2010 |
Keywords
- Adalimumab
- Biologics
- Infliximab
- Ulcerative colitis
ASJC Scopus subject areas
- Gastroenterology